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ABSTRACT
We attempt to identify the plasma membrane transporter in-
volved in the uptake of 59-deoxy-5-fluorouridine (59-DFUR), an
intermediate metabolite of capecitabine. This novel oral fluoro-
pyrimidine is used in cancer treatments and is a direct precur-
sor of the cytostatic agent 59-fluorouracil. We also examine the
role of the transporter in 59-DFUR cytotoxicity. The human
concentrative nucleoside transporter (hCNT1) was cloned from
human fetal liver and expressed in Xenopus laevis oocytes. The
two-electrode voltage-clamp technique was used to demon-
strate that 59-DFUR, but not capecitabine or 59-FU, is an
hCNT1 substrate. Then, hCNT1 was heterologously expressed
in the mammalian cell line Chinese hamster ovary-K1. Func-
tional expression was demonstrated by monitoring transport of
radiolabeled substrates and by using a monospecific polyclonal
antibody generated against the transporter. hCNT1-expressing
cells were more sensitive to 59-DFUR than vector-transfected
or wild-type cells. The sensitivity of the three cell types to other
agents such as cisplatin or 59-FU was identical. In conclusion,
this study shows that 1) the pharmacological profile of a nucle-
oside transporter can be determined by an electrophysiological
approach; 2) the hCNT1 transporter is involved in 59-DFUR
uptake; and 3) hCNT1 expression may increase cell sensitivity
to 59-DFUR treatment. This study also reports for the first time
the generation of an antibody against hCNT1, which may be
useful in the elucidation of the relationship between hCNT1
expression and tumor response to capecitabine treatment.
Capecitabine (Xeloda; N4-pentyloxycarbamyl-59-deoxy-5-
fluorocytidine) is a novel oral fluoropyrimidine derivative
that is active against a variety of solid tumors (Cassidy 1999;
Villalona-Calero et al., 1999; Van Cutsem et al., 2000). Cape-
citabine treatment results in 59-fluorouracil (59-FU) synthe-
sis inside tumor cells as a consequence of metabolic activa-
tion, which involves three sequential reactions (Verweij,
1999). The first is catalyzed by a hepatic enzyme, carboxy-
lesterase, and yields 59-deoxy-5-fluorocytidine, which is then
converted to 59-deoxy-5-fluorouridine (59-DFUR) by cytidine
deaminase. This enzyme is also highly expressed in liver,
although it can be present in various solid tumors. 59-DFUR
is the direct precursor of the cytotoxic drug 59-FU. This
conversion occurs mostly in tumors, which express thymidine
phosphorylase (dThdPase) activity at different levels (Yo-
shimura et al., 1990). In fact, this enzyme may limit 59-FU
production as suggested by the fact that heterologous expres-
sion of dThdPase in a variety of tumor cell lines increases
59-DFUR cytotoxicity (Patterson et al., 1995; Kato et al.,
1997; Evrard et al., 1999). However, 59-FU cytotoxicity also
depends on the activity of dihydropyrimidine dehydrogenase,
which inactivates 59-FU. The dThdPase/dihydropyrimidine
dehydrogenase ratio is variable among cancer types but it is
even more variable among patients, which indicates that it
may be a useful criterion for selecting patients for chemo-
therapy (Mori et al., 2000).
In this scenario of metabolic activation of capecitabine,
plasma membrane transporters may play an accessory or
even a key role, thus modulating the uptake into tumor cells
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of the active intermediate metabolite 59-DFUR. Recent evi-
dence suggests that most nucleoside-derived drugs are sub-
strates of transporters responsible for the uptake of natural
nucleosides (Yao et al., 1996; Schaner et al., 1997; Mackey et
al., 1998; 1999; Pastor-Anglada et al., 1998; Baldwin et al.,
1999). So far, two families of transporters have been identi-
fied in kinetic and molecular terms: the equilibrative family
(ENT), for which two isoforms, hENT1 and hENT2, have
been cloned, and the concentrative nucleoside transporter
family (CNT) for which two isoforms have also been charac-
terized at the cDNA level, hCNT1 and hCNT2. Whereas
hCNT1 may be involved in the uptake of pyrimidine-deriva-
tives, including fluoropyrimidines with anticancer proper-
ties, hCNT2 is a purine nucleoside-preferring transporter.
The CNT transporters show higher affinity for their sub-
strates than the ENTs (for recent reviews, see Wang et al.,
1997; Pastor-Anglada et al., 1998; Baldwin et al., 1999).
Here we have cloned and expressed the hCNT1 transporter
in Xenopus laevis oocytes and in CHO-K1 cells. The expres-
sion of a functional hCNT1 transporter in oocytes was dem-
onstrated by an electrophysiological approach, which was
used to determine the pharmacological profile of the trans-
porter (Lostao et al., 2000). Neither capecitabine nor 59-FU is
an hCNT1 substrate, although 59-DFUR is. The expression of
a functional hCNT1 transporter in CHO-K1 cells was dem-
onstrated by flux measurements of radiolabeled natural
nucleosides and by immunocytochemistry using a monospe-
cific polyclonal antibody generated against an N-terminal
oligopeptide of the hCNT1 protein. To our knowledge, this is
the first antibody against a human concentrative nucleoside
transporter to be reported in the literature. Interestingly,
according to the pharmacological profile of hCNT1, CHO-K1
cells expressing this transporter are more sensitive to 59-
DFUR, which suggests that its uptake contributes to drug
cytotoxicity and thus tumor sensitivity. If so, the effective-
ness of capecitabine may depend not only on the activities of
the enzymes but also on the transport process.
Materials and Methods
Cloning of the Human Fetal Liver hCNT1 Transporter. The
hCNT1 clone was obtained by amplification of an oligo(dT)-primed
cDNA library from human fetal liver (Marathon Ready cDNA,
CLONTECH, Palo Alto, CA), using a PCR approach with Advantage
2 Polymerase Mix (CLONTECH), as described previously (Lostao et
al., 2000). Primers HC1E (59-GCTGCACTGCATG GTTGCTGCTG-
GATGTGTTG-39) and HC1D (59-GGGAAGGGGCATGTGA GGGAC-
CCCAGGAGA-39), derived from the reported sequence for hCNT1
(GenBank accession number U62966), were used in a touchdown
PCR that produced a unique DNA band of approximately 2 kilobase
pairs. This PCR product was gel purified, used in an additional
reaction of dATP added to the 39 end with TaqPolymerase (Promega,
Madison, WI), again purified in a DNA clean-up column (Wizard
DNA Cleanup System; Promega), and finally ligated to the plasmid
pGEM-Teasy (pGEM-Teasy Vector System II; Promega) with T4
DNA Ligase (New England Biolabs). The construct pGEMT-hCNT1,
after Taq DyeDeoxy terminator cycle sequencing of both strands
(DNA sequencing kit, dRhodamine Terminator Cycle Sequencing;
PerkinElmer Life Science Products, Norwalk, CT) and aligning with
published sequence, confirmed the nature of the hCNT1 cDNA. The
hCNT1 cDNA was then inserted into the pBSII(KS) vector, which
contained a poly(A) tail of 54 bp from the original plasmid pBSI-
I(KS)-hSGLT1 (Hediger et al., 1987) as follows. pBSII(KS)-hSGLT1
was digested with NsiI, blunted with Klenow fragment, purified in a
DNA clean-up column, digested with SalI, and gel-purified. The
construct pGEMT-hCNT1 was digested in parallel. The two frag-
ments were ligated with T4 DNA Ligase as described above and the
product, pBSII(KS)-hCNT1-poly(A) tail-, was used to transform
Escherichia coli XL-1 Blue. Plasmid pBSII(KS)-hSGLT1 was kindly
donated by Dr. E. M. Wright (University of California Los Angeles,
Los Angeles, CA).
Expression of hCNT1 in X laevis Oocytes and Electrophys-
iological Studies.The plasmid containing the hCNT1 cDNA was
linearized with XbaI and cRNA synthesized using the T3 MEGAs-
cript kit (Ambion, Austin, TX) in the presence of m7G(59)ppp(59)G.
cRNA (50 ng ) was injected into X laevis oocytes, which were then
maintained at 18°C in Barth’s medium for 3 to 5 days. Electrophys-
iology experiments were performed to examine substrate-induced
Na1 inward currents using the two-electrode voltage-clamp method
(Hirayama et al., 1996; Lostao et al., 2000). The oocyte membrane
potential (Vm) was held at 250 mV and continuous current data were
recorded using Axoscope V 1.1.1.14 (Axon Instruments, Foster City,
CA).
The apparent affinity constant (K0.5) and the maximal current for
saturating cytidine and 59-DFUR (Imax) were obtained by fitting the
steady-state currents at each membrane potential to the equation:
I 5 Imax. [S]/(K0.5 1 [S]), where [S] is the substrate concentration,
using the nonlinear fitting method in SigmaPlot 4 (SPSS, Chicago,
IL). Natural nucleosides used in these experiments were purchased
from Sigma (St. Louis, MO). Capecitabine and 59-DFUR were kindly
donated by Roche (Fukuoka, Japan).
Expression of hCNT1 in CHO-K1 Cells. The hCNT1 cDNA was
also subcloned into a pCDNA3 vector and stably transfected into
CHO-K1 cells using Fugene (Roche). Putative hCNT1-expressing
clones were selected using geneticin treatment and several indepen-
dent clones were checked for hCNT1 activity, mRNA, and protein.
Wild-type (nontransfected) CHO-K1 cells and cells transfected with
the empty pCDNA3 vector were used as control cells in these exper-
iments.
hCNT1-related activity was measured in several independent
clones by monitoring the uptake of 1 mM uridine (Sigma), as de-
scribed previously (del Santo et al., 1998). Transport measurements
were performed by incubating cell monolayers in an uptake buffer,
supplemented with either sodium or choline chloride, in which [3H]u-
ridine was added at a specific activity of 1 mCi/nmol. This method
allows the calculation of Na1-dependent uptake rates. Incubations
were stopped by rapidly aspirating the uptake buffer and immediate
washing with a cold stop buffer, as described previously (del Santo et
al., 1998). The specificity of uridine transport was further studied by
inhibiting 1 mM uridine uptake by pyrimidine nucleosides and nu-
cleoside-derived drugs at a concentration of 100 mM.
Generation of a Monospecific Polyclonal Antibody against
the hCNT1 Protein. Expression of hCNT1 was also assessed by
confocal microscopy using a monospecific polyclonal antibody gener-
ated in our laboratory. The primary structure of hCNT1 protein was
analyzed on the basis of the prediction of transmembrane domains,
the position of the a-helix in the predicted secondary structure using
a program that combines the algorithms of Chou-Fasman and Rose,
the position of hydrophobicity peaks in the hydrophilicity plot using
the Kyte-Doolitle method with a window size of 9 amino acids, and,
finally, the Surface Probability and Flexibility Index plots according
to the algorithms of Boger and Karplus and Schulz, as described
previously (Felipe et al., 1998). An oligopeptide corresponding to
residues 48 to 69 was chosen on the basis of its putative antigenicity
and the unique nature of this sequence. This oligopeptide was cou-
pled to keyhole limpet hemocyanin, emulsified with an equal volume
of Freund’s adjuvant, and injected into rabbits. The IgG fraction of
the immunoreactive antisera was purified using a protein A-Sepha-
rose CL-4B column and used for further immunoassays. Cells were
plated onto glass coverslips. Forty-eight hours after plating, the cells
were washed in phosphate-buffered saline (PBS) and fixed with a 2%
p-formaldehyde solution supplemented with 0.05% saponin for 15
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min. After fixation, the cells were washed twice in 20 mM glycine-
PBS for 10 min. After blocking with 1% bovine serum albumin in 20
mM glycine/PBS for 15 min, the coverslips were incubated with a
1:40 diluted hCNT1 primary antibody for 1 h. After the incubation,
the cells were washed three times in PBS, incubated with an anti-
rabbit IgG antiserum coupled to fluorescein (1:50) as a second anti-
body, washed in PBS, and then mounted onto glass slides using
immunofluor mounting solution. A confocal microscope was used for
observation and photography.
Antibody Specificity Assay. Briefly, frozen tissue was air-dried,
then fixed with 3% paraformaldehyde/PBS for 5 min. After washing
in PBS, samples were permeabilized with 0.1% Triton X-100/PBS.
Sections were incubated in 3% H2O2/methanol for 30 min to block
endogenous peroxidases before blocking unspecific bindings with
normal blocking serum (0.1 M glycine/1% bovine serum albumin/5%
goat normal serum/PBS) for 20 min. Slides were incubated overnight
at 4°C in a humidified chamber with a 1:125 diluted hCNT1 primary
antibody incubated previously with hCNT1 peptide (residues 48–69)
at a final concentration of 25 mg/ml for 15 h at room temperature in
a shaker. After two washes in PBS, a 1:200 diluted second antibody
Anti-rabbit IgG biotin conjugate (Sigma) was added for 30 min at
room temperature. Slides were then incubated with a 1:250 dilution
of Streptavidin horseradish peroxidase-conjugated (Zymed Labora-
tories, South San Francisco, CA)/PBS for 30 min. Samples were
revealed with aminoethyl carbazole substrate (Zymed). Finally, spec-
imens were counterstained with Mayer’s hematoxylin and mounted
the coverslips with an aqueous mounting medium.
Cytotoxicity Assays. The cytotoxicity assays were performed by
seeding the three cell lines, CHO-K1 wild-type (CHO-K1 WT),
CHO-K1 transfected with the vector alone (CHO-K1 PC), and
CHO-K1 cells transfected with the hCNT1 transporter cDNA (CHO-
K1 HC1), at a density of 2500 cells/cm2. Twenty-four hours after
seeding, cultures were exposed for 90 min to the cytotoxic agents
(capecitabine, 59-DFUR, 59-FU or cisplatin). Viability was assessed
24, 48, 72, and 96 h after the addition of the putative cytotoxic drugs
by counting the cells in the monolayer after trypsinization of the
cultures (Multisizer; Beckman Coulter, Inc., Fullerton, CA). Viability
determinations using trypan blue exclusion gave identical results
(not shown). Viability was then calculated on a percentage basis by
comparing the number of viable cells after treatment with that of a
culture that had not been exposed to any cytotoxic drug.
Results
Cloning of the hCNT1 cDNA from Human Fetal
Liver. A 2.1-kilobase pair fragment was amplified and
cloned from a human fetal liver cDNA library, as indicated
under Materials and Methods. This fragment contained the
hCNT1 cDNA as deduced from sequencing of both ends of the
fragment. Amplification did not result in the incorporation of
any mutation inside the cDNA sequence and, as indicated
below, resulted in a functional protein when expressed het-
erologously. However, this cDNA contained a 116-bp seg-
ment at the 59 end before the ATG start codon that is not
present in the original reported sequence, which was ob-
tained from adult human small intestine. This new sequence
(GenBank number AF309632) may be the result of different
RNA processing or splicing or alternate use of promotors in
the hCNT1 gene, which may be either tissue-specific or de-
velopmentally regulated, as long as this cDNA was indeed
isolated from a different tissue (liver instead of small intes-
tine) but also from fetuses instead of adults.
Heterologous Expression of the hCNT1 cRNA in
Oocytes from X laevis. hCNT1 expression in X laevis
oocytes was monitored by the two-electrode voltage-clamp
technique, and representative currents generated by cyti-
dine, a natural pyrimidine nucleoside and nucleoside deriv-
ative, are shown in Fig. 1. Cytidine and 59-DFUR induced
inward currents, whereas neither capecitabine nor 59-FU
induced any significant current, in the hCNT1-expressing
oocytes. Similar results were obtained with oocytes from two
different frogs. The concentration dependence of Na1-depen-
dent induced currents generated by cytidine and 59-DFUR
was also studied. A representative kinetic analysis is shown
in Fig. 2. Although Vmax values varied among hCNT1-ex-
pressing oocytes, the Km values were reproducible. Apparent
Km values derived from these measurements were lower for
cytidine than for 59-DFUR, but the current intensity gener-
ated by 59-DFUR was markedly higher.
Expression of hCNT1 in CHO-K1 Cells. The hCNT1
transporter was also expressed in CHO-K1 cells. Selected
clones were checked for Na1-dependent nucleoside transport
activity as a functional measurement of hCNT-1 expression,
because wild-type CHO-K1 cells only express equilibrative
nucleoside transport system(s). Up to six independent clones
were analyzed. All had significant Na1-dependent uridine
transport activity (not shown), but clone 1 was chosen for
further experiments because of its high Na1-dependent uri-
dine transport activity (Fig. 3A). CHO-K1 cells transfected
with the pCDNA3 vector alone (without hCNT1) showed
similar uptake rates to the wild-type (Fig. 3A.). Nevertheless,
to check for the pyrimidine-preferring nature of the ex-
pressed activity, the classical feature of the hCNT1 trans-
porter, a panel of putative cis-inhibitors of Na1-dependent
nucleoside transport was analyzed (Fig. 3B.). Cytidine com-
pletely inhibited Na1-dependent uridine uptake, whereas
Formycin-B (somehow a specific substrate for hCNT2, a pu-
rine-preferring transporter) did not exert any significant in-
hibition on Na1-dependent uridine transport. In agreement
with the electrophysiological data, 59-DFUR, but not capecit-
abine, inhibited hCNT1-mediated uptake. The Na1-indepen-
dent components of nucleoside transport were also analyzed
in all three cell lines, (Fig. 4). This was done to determine
Fig. 1. Na1 currents generated by hCNT1 in the presence of cytidine and
nucleoside derivative drugs. Oocyte was continuously perfused with Na1
buffer (open box). The addition of 0.5 mM cytidine or 59-DFUR induced an
inward current of 151 and 764 nA, respectively. Capecitabine or 59-FU
(0.5 mM) did not induce any current. After the perfusion of each sub-
strate, the oocyte was washed out in Na1-free medium (filled box). 59-FU
was tested in a different oocyte in which 0.5 mM uridine induced 52 nA
of inward Na1 current. Both oocytes were used 5 days after injection with
hCNT1 cRNA and the membrane potential was held at 250 mV.
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whether the heterologous expression of the hCNT1 trans-
porter modified the endogenous transport activity. Wild-type
CHO-K1 cells only express an equilibrative transport activ-
ity, which, according to the inhibition pattern, is of the es
type, because it is mostly inhibited by low concentrations of
nitrobenzylthioinosine and dipyridamole (not shown). es-
Type transport activity was the same in the three cell lines
(wild-type, CHO-K1 cells transfected with the vector alone,
and clone 1) expressing the hCNT1 transporter (Fig. 4).
Further demonstration of hCNT1 expression in CHO-K1
cells came from the analysis of hCNT1 mRNA by Northern
blot using the previously cloned hCNT1 gen as probe (not
shown) and from immunocytochemistry (Fig. 5). Only cells
functionally expressing an hCNT1-type of transporter re-
acted with the antibody generated. Significant staining in-
side the cells may be the result of the overexpression of the
transporter protein in this stable cell model. Wild-type cells
and cells transfected with the empty vector did not show
significant immunoreactivity (Fig. 5), nor did the preimmune
antiserum from the same rabbit (data not shown). Obviously,
the hCNT1 mRNA was not detected in WT and PC cells. To
provide independent evidence of the selectivity of the anti-
body raised against the hCNT1 transporter, biopsies from
human intestine were stained in either the absence or the
presence of an excess of the synthetic peptide, which success-
fully blocked the immunoreactivity, further demonstrating
the specificity of this monospecific polyclonal antibody (Fig.
6).
Effect of Heterologous hCNT1 Expression on Cell
Sensitivity to 5*-DFUR. The effect of heterologous hCNT1
expression on the sensitivity of CHO-K1 cells to 59-DFUR
was analyzed. Cells expressing hCNT1 were more sensitive
to 59-DFUR (Fig. 7) than the wild-type cells or cells trans-
fected with the empty vector. In independent experiments,
the expression of hCNT1 always resulted in sensitization of
cells to 59-DFUR treatment by a factor of 2.5- to 5-fold,
depending on the experiment. The relative role of the endog-
enous equilibrative nucleoside transporters in 5-DFUR cyto-
toxicity was assessed by inhibiting these transport activities
with 10 mM dipyridamole (Table 1). Dipyridamole induced
significant resistance to 59-DFUR in wild-type CHO-K1 and
empty vector-transfected cells, but it barely modified the IC50
value for 59-DFUR in cells expressing the hCNT1 transporter
(Table 1). Obviously, the hCNT1-mediated sensitivity was
specific for hCNT1 substrates, because cell death induced by
other genotoxic agents, such as 59-FU and cisplatin, was
independent of the expression of the hCNT1 transporter (not
shown). Capecitabine had no toxic effect on either cell line
(not shown).
Discussion
This study identifies the plasma membrane transporter
responsible for 59-DFUR transport. 59-DFUR is the immedi-
Fig. 2. Na1 inward current generated by 59-DFUR and cytidine as a
function of their concentrations. Experiment was performed on a single
oocyte, 6 days after injection with hCNT1 cRNA. The membrane potential
was held at 250 mV. Kinetic constants were obtained by fitting the
currents obtained at 6 to 7 different concentrations (from 10 to 1000 mM)
to the equation under Materials and Methods. Dashed lines correspond to
the predicted curves using the kinetic constants.
Fig. 3. Characterization of uridine transport activity in CHO-K1 cell line stably transfected with hCNT1 gene. CHO-K1 cell types (WT, wild-type; PC,
vector alone; HC1, hCNT1) cultured as described under experimental procedures were incubated with 1 mM uridine either in a NaCl or a choline
chloride medium for 90 s. Values are the mean 6 S.E. of three independent experiments. A, characterization of uridine transport activity in the
different cell types. The transfection of hCNT1 gene into CHO-K1 induces a previously nonexistent Na1- dependent uridine uptake. B, inhibition
profile of hCNT1 induced Na1-dependent transport activity by 100 mM putative cis-inhibitors. Na1-dependent transport activity was calculated by
subtracting the rates measured in choline chloride medium from those obtained in the Na1-medium.
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ate precursor of 59-FU and is taken up by solid tumors after
being endogenously synthesized in patients treated with the
prodrug capecitabine. As indicated above, capecitabine is one
of the most novel chemotherapeutical agents rationally de-
signed to generate the drug 59-FU in a relatively tumor-
specific manner (Cassidy 1999; Verweij, 1999; Villalona-
Calero et al., 1999; Van Cutsem et al., 2000). This is achieved
because the enzyme converting 59-DFUR into 59-FU, thymi-
dine phosphorylase, is highly expressed in tumors (Yo-
shimura et al., 1990). Nevertheless, the activity of this en-
zyme is highly variable, which may have some treatment
prognostic relevance, especially when it is referred to that of
the 59-FU inactivating enzyme dihydropyrimidine dehydro-
genase (Mori et al., 2000).
Advantage was taken of the ability of the human pyrimi-
dine-preferring nucleoside transporter 1 (hCNT1) to gener-
ate substrate-evoked currents, when heterologously ex-
pressed in X laevis oocytes, to determine whether
capecitabine or its endogenously synthesized metabolites are
hCNT1 substrates. The use of electrophysiology in the eluci-
dation of the pharmacological profile of the CNT transporters
has been developed very recently (Mackey et al., 1999; Lostao
et al. 2000; Dresser et al., 2000) and opens the possibility for
rapid and massive screening for uptake of newly developed
nucleoside-derived drugs, as shown here.
This study suggests that the transporter involved in 59-
DFUR uptake also plays a role in determining drug sensitiv-
ity. Although extensive recent work has reported the positive
effects of heterologously expressing thymidine phosphorylase
on promoting sensitivity to 59-DFUR (Patterson et al., 1995;
Kato et al., 1997; Evrard et al., 1999), here it is shown that
the expression of a specific transporter protein also promotes
increased sensitivity to this prodrug. Stable expression of
hCNT1 confers CHO-K1 cells with increased sensitivity to
Fig. 4. Inhibition profile of Na1-independent transport activity in the
three cell types. CHO-K1 cells (WT, wild-type; PC, vector alone; HC1,
hCNT1) were incubated, as indicated under Materials and Methods, in
the presence of 1 mM uridine in a Na1-free transport medium (choline
chloride). Values are the mean 6 S.E. of three independent experiments.
Fig. 5. Immunocytochemistry of hCNT1 protein in the three independent clones. In this representative result, no positive signal is present in wild-type
(A) or in vector transfected (B) cell clone. In contrast, the antibody raised against the protein hCNT1 specifically recognizes it in the clone HC1 (C),
which presents the stable expression of the hCNT1 gene.
Fig. 6. Immunohistochemistry assay in tissue samples from human intestine, counterstained with Mayer’s hematoxylin. A, histochemical staining for
hCNT1. B, blockade of specific hCNT1 antibody immunoreactivity by competition with an excess of pure hCNT1 peptide.
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59-DFUR. This effect is significant and specific to this com-
pound, because other nucleoside-derived and non–nucleo-
side-derived genotoxics do not show increased therapeutic
indexes associated with hCNT1 expression. Moreover, this
effect is also specific to the hCNT1 transporter because its
heterologous expression has no effect on the endogenous
transport activity, which is mostly of the es-type. However,
the endogenous equilibrative transporter is also likely to
contribute to the cytotoxic action of 59-DFUR because 1) cells
not expressing hCNT1 also die after treatment and 2) inhi-
bition of this transport by dipyridamole results in strong
resistance to the prodrug. Nevertheless, the evidence pro-
vided here, which demonstrates that blocking of the endoge-
nous nucleoside transport activity has little effect on 59-
DFUR cytotoxicity in hCNT1-expressing cells, is consistent
with the concept that in cells coexpressing equilibrative and
concentrative nucleoside transporters, the CNT proteins (in
this specific case the hCNT1 isoform) are key determinants of
nucleoside bioavailability and cytotoxicity. This is in agree-
ment with the observation that the IC50 value for the cyto-
toxic action of 59-DFUR on hCNT1-expressing CHO-K1 cells
closely resembles the reported apparent Km value of the
hCNT1 transporter for this compound, irrespective of the
endogenous equilibrative nucleoside transport activity. On
the other hand, the lack of effect of capecitabine on the three
cell lines tested may be a result of the need for metabolic
activation or, more likely, the inability of CHO-K1 cells to
take up this compound efficiently. This is based upon the
evidence that capecitabine is not an hCNT1 substrate and
the fact that capecitabine did not significantly inhibit the
endogenous equilibrative nucleoside transport activity. In
fact, the identification of the capecitabine transporter(s) is
still an open question that is currently being addressed in our
laboratory.
The evidence that 59-DFUR-evoked currents are greater
than those evoked by the natural substrate cytidine, suggests
that, whereas the binding of the prodrug to the transporter
may be less efficient, once bound, translocation occurs more
rapidly than when cytidine is the substrate.
The reported cytotoxic effect of 59-DFUR may indeed be
much lower in CHO-K1 cells than in human tumor cells,
because this cell line, although easy to transfect, select, and
grow, is neither human nor tumoral in origin and may show
very low thymidine phosphorylase activity. This suggests
that the role of the transporter in drug bioavailability and
cytotoxicity may be even greater in cells expressing high
thymidine phosphorylase-specific activity.
hCNT1 may determine cell toxicity to a variety of fluoro-
pyrimidines, because it has also been demonstrated that
gemcitabine is an hCNT1 substrate (Mackey et al., 1998;
1999; Lostao et al., 2000). It is probable that the expression
levels of this protein may determine drug bioavailability and
cytotoxicity. In this context, the present study also provides
the characterization of a monospecific polyclonal antibody
against the human isoform of CNT1, which may prove useful
in further clinical studies using human biopsies from pa-
tients treated with capecitabine. We have shown that CNT
expression, at least in liver parenchymal cells, depends on
the differentiation status of the cell (del Santo et al., 1998)
and in a transgenic rat model of hepatocarcinogenesis, we
have demonstrated a selective loss of CNT1 expression in
adenomas and hepatocarcinomas (Dragan et al., 2000). Un-
fortunately, the antibody used in the present study did not
cross-react with human tissue and so the provision of a new
antibody against the human isoform of this drug transporter
is of interest. Evidence that CNT expression depends on
differentiation and/or proliferation has also been provided in
other cell models, such as human B lymphocytes (Soler et al.,
1998, 2000) and cell lines derived from human pancreatic
tumors (J. Garcı´a-Manteiga, J. Calbo´, A. Felipe, F. J. Casado,
A. Mazo, and M. Pastor-Anglada, submitted).
In summary, this study demonstrates that the human con-
centrative nucleoside transporter hCNT1 is the 59-DFUR
transporter and its expression confers sensitivity to the drug.
We also provide the characterization of an hCNT1 antibody,
which may be useful in further clinical studies.
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